We demonstrated a potent ex vivo cytotoxic targeting of CD19-CAR T cells against RUNX1mut BP-CML blasts in both myeloid-BP and lymphoid-BP patients. This evidence concerns the gene CD19 and chronic myelogenous leukemia, BCR-ABL1 positive.